Condom migration resulting from circumcision, microbicides and vaccines: Brief review and methodological considerations

Sexual Health

Volumn 9, Issue 1, 2012, Pages 96-102

  Crosby, Richard A ^a,b   Ricks, Janelle ^a   Young, April ^c  

^a UNIVERSITY OF KENTUCKY COLLEGE OF PUBLIC HEALTH   (United States)

^b Kinsey Institute for Research on Sex Gender and Reproduction   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

condom use; contraceptives; risk; safer sex

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MICROBICIDE;

CIRCUMCISION; CONDOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; OUTCOME ASSESSMENT; REVIEW; SAFE SEX; SEXUAL BEHAVIOR; SEXUAL COUNSELING; SYSTEMATIC REVIEW;

ANTI-INFECTIVE AGENTS, LOCAL; CAUSALITY; CIRCUMCISION, MALE; CONDOMS; EVIDENCE-BASED MEDICINE; FEMALE; FOREIGN-BODY MIGRATION; HIV INFECTIONS; HUMANS; LATEX; LUBRICANTS; LUBRICATION; MALE; VACCINES;

EID: 84857495605     PISSN: 14485028     EISSN: 14498987     Source Type: Journal    
DOI: 10.1071/SH11091     Document Type: Review

References (80)

1. Cassell MM, et al. Risk compensation: the Achilles' heel of innovations in HIV prevention? BMJ (Int Ed) 2006; 332: 605-607. (Pubitemid 44365764)
2. Novak DP, Karlsson RB. Gender differed factors affecting male condom use. A population-based study of 18-year-old Swedish adolescents. Int J Adolesc Med Health 2005; 17(4): 379-90. doi:10.1515/IJAMH.2005.17.4.379 (Pubitemid 43072268)
3. Roye CF. Condom use by Hispanic and African-American adolescent girls who use hormonal contraception. J Adolesc Health 1998; 23(4): 205-11. doi:10.1016/S1054-139X(97)00264-4 (Pubitemid 28436513)
4. Sangi-Haghpeykar H, Posner SF, Poindexter AN. Consistency of condom use among low-income hormonal contraceptive users. Perspect Sex Reprod Health 2005; 37(4): 184-91. doi:10.1363/ 3718405 (Pubitemid 43089511)
5. Sieving R, et al. Cognitive and behavioral predictors of sexually transmitted disease risk behavior among sexually active adolescents. Arch Pediatr Adolesc Med 1997; 151(3): 243-51. (Pubitemid 27133206)
6. Smith JL, et al. Young males' perspectives on pregnancy, fatherhood and condom use: where does responsibility for birth control lie? Sex Reprod Healthc 2011; 2(1): 37-42. doi:10.1016/j.srhc.2010.10.002
7. Weisman CS, et al. Consistency of condom use for disease prevention among adolescent users of oral contraceptives. Fam Plann Perspect 1991; 23(2): 71-4. doi:10.2307/2135452
8. Cates W, Holmes KK, Sparling PF, Mardh P. Contraception, contraceptive technology, and STDs. Sex Transm Dis 1999; 3: 1067-78.
9. Rosenthal SL, et al. Experience with side effects and health risks associated with Norplant implant use in adolescents. Contraception 1995; 52(5): 283-5. doi:10.1016/0010-7824(95)00212-S
10. Pruitt SL, et al. Condom use among sterilized and nonsterilized women in county jail and residential treatment centers. Womens Health Issues 2010; 20(6): 386-93. doi:10.1016/j.whi.2010.06.007
11. Sangi-Haghpeykar H, Horth F, Poindexter AN. Condom use among sterilized and nonsterilized Hispanic women. Sex Transm Dis 2001; 28 (9): 546-51. doi:10.1097/00007435-200109000-00013 (Pubitemid 32852662)
12. Semaan S, Lauby J, Walls C. Condom use with main partners by sterilized and non-sterilized women. Women Health Issues 1997; 25 (2): 65-85. doi:10.1300/J013v25n02-04 (Pubitemid 27394036)
13. Behets F, et al. Acceptability and feasibility of continuous diaphragm use among sex workers in Madagascar. Sex Transm Infect 2005; 81(6): 472-6. doi:10.1136/sti.2005.015107 (Pubitemid 41811328)
14. Behets FM, et al. Evidence-based planning of a randomized controlled trial on diaphragm use for prevention of sexually transmitted infections. Sex Transm Dis 2008; 35(3): 238-42. doi:10.1097/ OLQ.0b013e31815abaa2 (Pubitemid 351619528)
15. Gallo MF, et al. Assessment of changes in condom use among female sex workers in a prospective cohort study introducing diaphragm use for disease prevention. Am J Epidemiol 2010; 172(5): 606-12. doi:10.1093/aje/kwq158
16. Padian NS, et al. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: A randomised controlled trial. Lancet 2007; 370(9583): 251-61. doi:10.1016/S0140-6736(07) 60950-7 (Pubitemid 47069513)
17. Posner SF, et al. Introducing diaphragms into the mix: what happens to male condom use patterns? AIDS Behav 2005; 9(4): 443-9. doi:10.1007/s10461-005- 9016-z (Pubitemid 43207840)
18. van der Straten A, et al. The use of the diaphragm instead of condoms in a phase III diaphragm trial. AIDS Behav 2009; 13(3): 564-72. doi:10.1007/s10461-008-9504-z
19. van der Straten A, Cheng H, Minnis AM. Change in condom and other barrier method use during and after an HIV prevention trial in Zimbabwe. J Int AIDS Soc 2010; 13: 39-49. doi:10.1186/1758- 2652-13-39
20. Bukusi EA, et al. Adherence to diaphragm use for infection prevention: a prospective study of female sex workers in Kenya. Infect Dis Obstet Gynecol 2009; 2009: 420196. doi:10.1155/2009/ 420196
21. Belzer M, et al. Advance supply of emergency contraception: a randomized trial in adolescent mothers. J Pediatr Adolesc Gynecol 2005; 18(5): 347-54. doi:10.1016/j.jpag.2005.06.007 (Pubitemid 41395254)
22. Chin-Quee DS, et al. Bridging emergency contraceptive pill users to regular contraception: results from a randomized trial in Jamaica. Contraception 2010; 81(2): 133-9. doi:10.1016/j.contraception. 2009.08.015
23. Ekstrand M, et al. Advance provision of emergency contraceptive pills reduces treatment delay: a randomised controlled trial among Swedish teenage girls. Acta Obstet Gynecol Scand 2008; 87(3): 354-9. doi:10.1080/ 00016340801936024 (Pubitemid 351317481)
24. Ellertson C, et al. Emergency contraception: randomized comparison of advance provision and information only. Obstet Gynecol 2001; 98 (4): 570-5. doi:10.1016/S0029-7844(01)01506-X (Pubitemid 32907448)
25. Gray RH, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007; 369(9562): 657-66. doi:10.1016/S0140- 6736(07)60313-4
26. Polis CB, et al. Advance provision of emergency contraception for pregnancy prevention: a meta-analysis. Obstet Gynecol 2007; 110(6): 1379-88. doi:10.1097/01.AOG.0000295603.84568.f6 (Pubitemid 351326084)
27. Walker DM, et al. Emergency contraception use is correlated with increased condom use among adolescents: results from Mexico. J Adolesc Health 2004; 35(4): 329-34. doi:10.1016/j.jadohealth. 2004.07.001 (Pubitemid 39265366)
28. Eaton LA, Kalichman SC. Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies. Curr HIV/AIDS Rep 2007; 4: 165-72. doi:10.1007/s11904-007-0024-7
29. Potts MH, Halperin DT, Kirby D, Swidler A, Marseille E, Klausner JD, et al. Reassessing HIV prevention. Science 2008; 320: 749-50. doi:10.1126/science. 1153843 (Pubitemid 351929614)
30. Weiss HA, Quigley MA, Hayes RJ. Male circumcision and risk of HIV infection in sub-Saharan Africa: a systematic review and metaanalysis. AIDS 2000; 14(15): 2361-70. doi:10.1097/00002030- 200010200-00018
31. Reynolds SJ, et al. Male circumcision and risk of HIV-1 and other sexually transmitted infections in India. Lancet 2004; 363(9414): 1039-40. doi:10.1016/S0140-6736(04)15840-6 (Pubitemid 38410778)
32. Riess TH, et al. "When I was circumcised I was taught certain things": risk compensation and protective sexual behavior among circumcised men in Kisumu, Kenya. PLoS ONE 2010; 5(8): e12366. doi:10.1371/ journal.pone.0012366
33. Andersson KM, Owens DK, Paltiel AD. Scaling up circumcision programs in southern Africa: the potential impact of gender disparities and changes in condom use behaviors on heterosexual HIV transmission. AIDS Behav 2011; 15(5): 938-48. doi:10.1007/ s10461-010-9784-y
34. Agot KE, et al. Male circumcision in Siaya and Bondo Districts, Kenya: prospective cohort study to assess behavioral disinhibition following circumcision. J Acquir Immune Defic Syndr 2007; 44(1): 66-70. doi:10.1097/01.qai.0000242455.052 74.20 (Pubitemid 46052222)
35. Auvert B, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005; 2(11): e298. doi:10.1371/journal.pmed. 0020298
36. Bailey RC, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007; 369 (9562): 643-56. doi:10.1016/S0140-6736(07)60312-2 (Pubitemid 46281312)
37. Ramjee G, et al. Acceptability of Carraguard, a candidate microbicide and methyl cellulose placebo vaginal gels among HIV-positive women and men in Durban, South Africa. AIDS Res Ther 2007; 4: 20-29. doi:10.1186/1742-6405-4-20 (Pubitemid 350167991)
38. Foss AM, et al. Shifts in condom use following microbicide introduction: should we be concerned? AIDS 2003; 17(8): 1227-37. doi:10.1097/00002030- 200305230-00015 (Pubitemid 36675364)
39. Guest G, et al. Changes in sexual behavior during a safety and feasibility trial of a microbicide/diaphragm combination: an integrated qualitative and quantitative analysis. AIDS Educ Prev 2007; 19(4): 310-20. doi:10.1521/aeap.2007.19.4.310 (Pubitemid 47281280)
40. Holmes WR, Maher L, Rosenthal SL. Attitudes of men in an Australian male tolerance study towards microbicide use. Sex Health 2008; 5(3): 273-8. doi:10.1071/SH07093
41. McMahon JM, et al. Potential impact of vaginal microbicides on HIV risk among women with primary heterosexual partners. J Assoc Nurses AIDS Care 2011; 22(1): 9-16. doi:10.1016/j.jana.2010.05.001
42. Chen FH. The impact of microbicides and changes in condom usage on HIV prevalence in men and women. AIDS 2006; 20(11): 1551-3. doi:10.1097/01.aids. 0000237372.38939.5d (Pubitemid 44100217)
43. Lurie MN, et al. The impact of migration on HIV-1 transmission in South Africa: a study of migrant and nonmigrant men and their partners. Sex Transm Dis 2003; 30(2): 149-56. doi:10.1097/ 00007435-200302000-00011 (Pubitemid 36184364)
44. Sanders S, Yarber WL, Kaufman EL, Crosby RA, Graham CA, Milhausen RR. Condom use errors and problems: a global view. Sex Health 2012; 9(1): 81-95.
45. Newman PA, et al. Preventive HIV vaccine acceptability and behavioral risk compensation among a random sample of high-risk adults in Los Angeles (LA VOICES). Health Serv Res 2009; 44(6): 2167-79. doi:10.1111/j.1475-6773.2009. 01039.x
46. Blower SM, McLean AR. Prophylactic vaccines, risk behavior change, and the probability of eradicating HIV in San Francisco. Science 1994; 265(5177): 1451-4. doi:10.1126/science.8073289 (Pubitemid 24306799)
47. Jackson DJ, et al. Acceptability of HIV vaccine trials in high-risk heterosexual cohorts in Mombasa, Kenya. AIDS 1995; 9(11): 1279-84. doi:10.1097/00002030-199511000-00010
48. Chesney MA, Chambers DB, Kahn JO. Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note. J Acquir Immune Defic Syndr 1997; 16(4): 266-71. doi:10.1097/00042560-199712010-00007
49. Blower S, Schwartz EJ, Mills J. Forecasting the future of HIV epidemics: the impact of antiretroviral therapies & imperfect vaccines. AIDS Rev 2003; 5(2): 113-25. (Pubitemid 36873900)
50. Newman PA, et al. Challenges for HIV vaccine dissemination and clinical trial recruitment: if we build it, will they come? AIDS Patient Care STDS 2004; 18(12): 691-701. doi:10.1089/apc.2004.18.691 (Pubitemid 40066161)
51. Fonseca MGP, et al. Modeling HIV vaccines in Brazil: assessing the impact of a future HIV vaccine on reducing new infections, mortality and number of people receiving ARV. PLoS ONE 2010; 5(7): e11736-11736. doi:10.1371/journal. pone.0011736
52. Andersson KM, et al. Predicting the impact of a partially effective HIV vaccine and subsequent risk behavior change on the heterosexual HIV epidemic in low- and middle-income countries: a South African example. J Acquir Immune Defic Syndr 2007; 46(1): 78-90. (Pubitemid 47507437)
53. Newman PA, et al. Posttrial HIV vaccine adoption: concerns, motivators, and intentions among persons at risk for HIV. J Acquir Immune Defic Syndr 2004; 37(3): 1393-403. doi:10.1097/01.qai. 0000127064.84325.ad (Pubitemid 39435054)
54. Newman PA, et al. HIV risk and prevention in a post-vaccine context. Vaccine 2004; 22(15-16): 1954-63. doi:10.1016/j.vaccine.2003. 10.031 (Pubitemid 38581065)
55. Suraratdecha C, et al. The private demand for an AIDS vaccine in Thailand. Health Policy 2005; 71(3): 271-87. doi:10.1016/j.healthpol. 2004.05.005 (Pubitemid 40203401)
56. Suhadev M, et al. Factors associated with willingness to participate in HIV vaccine trials among high-risk populations in South India. AIDS Res Hum Retroviruses 2009; 25(2): 217-24. doi:10.1089/ aid.2007.0312
57. Crosby RA, Holtgrave DR. Will sexual risk behaviour increase after being vaccinated for AIDS? Int J STD AIDS 2006; 17(3): 180-4. doi:10.1258/ 095646206775809204
58. Bartholow BN, et al. HIV sexual risk behavior over 36 months of follow-up in the world's first HIV vaccine efficacy trial. J Acquir Immune Defic Syndr 2005; 39(1): 90-101. doi:10.1097/01. qai.0000143600.41363.78
59. Guest G, et al. HIV vaccine efficacy trial participation: men who have sex with men's experiences of risk reduction counselling and perceptions of risk behaviour change. AIDS Care 2005; 17(1): 46-57. doi:10.1080/ 09540120412331305124 (Pubitemid 40175531)
60. Newman PA, et al. Preventive HIV vaccine acceptability and behavioral risk compensation among high-risk men who have sex with men and transgenders in Thailand. Vaccine 2010; 28: 958-64. doi:10.1016/j.vaccine.2009.10.142
61. Lee SJ, et al. HIV vaccine acceptability among immigrant Thai residents in Los Angeles: a mixed-method approach. AIDS Care 2008; 20(10): 1161-8. doi:10.1080/09540120701855375
62. Newman PA, et al. Community heroes or "high-risk" pariahs? Reasons for declining to enroll in an HIV vaccine trial. Vaccine 2008; 26(8): 1091-7. doi:10.1016/j.vaccine.2007.12.016
63. Nyamathi AM, et al. Perceptions of a community sample about participation in future HIV vaccine trials in south India. AIDS Behav 2007; 11(4): 619-27. doi:10.1007/s10461-006-9173-8 (Pubitemid 46828774)
64. Crosby RA, Holtgrave D. Will sexual risk behavior increase after being vaccinated for AIDS? Int J STD AIDS 2006; 17: 180-4. doi:10.1258/ 095646206775809204
65. Sayles JN, et al. Future HIV vaccine acceptability among young adults in South Africa. Health Educ Behav 2010; 37(2): 193-210. doi:10.1177/ 1090198109335654
66. Newman PA, et al. HIV risk and prevention in a post-vaccine context. Vaccine 2004; 22(15-16): 1954-63. doi:10.1016/j.vaccine.2003. 10.031 (Pubitemid 38581065)
67. Lampinen TM, et al. Sexual risk behaviour of Canadian participants in the first efficacy trial of a preventive HIV-1 vaccine. Canadian Medical Association Journal 2005; 172(4): 479-83. doi:10.1503/ cmaj.1031785 (Pubitemid 40278473)
68. van Griensven F, et al. Lack of increased HIV risk behavior among injection drug users participating in the AIDSVAX B/E HIV vaccine trial in Bangkok, Thailand. AIDS 2004; 18(2): 295-301. doi:10.1097/ 00002030-200401230- 00020 (Pubitemid 38253453)
69. Francis DP, et al. Candidate HIV/AIDS vaccines: lessons learned from the world's first phase III efficacy trials. AIDS 2003; 17(2): 147-56. doi:10.1097/00002030-200301240-00003 (Pubitemid 36183039)
70. Bishai D, et al. Determinants of personal demand for an AIDS vaccine in Uganda: contingent valuation survey. Bull World Health Organ 2004; 82(9): 652-60. (Pubitemid 39278540)
71. Crosby R, et al. A brief, clinic-based, safer sex intervention for heterosexual African American men newly diagnosed with an STD: a randomized controlled trial. Am J Public Health 2009; 99: S96-103. doi:10.2105/AJPH.2007. 123893
72. Darbes L, et al. The efficacy of behavioral interventions in reducing HIV risk behaviors and incident sexually transmitted diseases in heterosexual African Americans. AIDS 2008; 22(10): 1177-94. doi:10.1097/QAD.0b013e3282ff624e
73. Dilley JW, et al. Brief cognitive counseling with HIV testing to reduce sexual risk among men who have sex with men: results from a randomized controlled trial using paraprofessional counselors. J Acquir Immune Defic Syndr 2007; 44(5): 569-77. doi:10.1097/QAI.0b013e318033ffbd (Pubitemid 46594902)
74. Jemmott LS, Jemmott JB, O'Leary A. Effects on sexual risk behavior and STD rate of brief HIV/STD prevention interventions for African American women in primary care settings. Am J Public Health 2007; 97(6): 1034-40. doi:10.2105/AJPH.2003.020271 (Pubitemid 351181925)
75. Jones KT, et al. Evaluation of an HIV prevention intervention adapted for Black men who have sex with men. Am J Public Health 2008; 98 (6): 1043-50. doi:10.2105/AJPH.2007.120337 (Pubitemid 351793383)
76. Lyles CM, et al. Best-evidence interventions: findings from a systematic review of HIV behavioral interventions for US populations at high risk, 2000-2004. Am J Public Health 2007; 97 (1): 133-43. doi:10.2105/AJPH.2005.076182 (Pubitemid 46067695)
77. Rietmeijer CA. Risk reduction counselling for prevention of sexually transmitted infections: how it works and how to make it work. Sex Transm Infect 2007; 83(1): 2-9. doi:10.1136/sti.2005.017319 (Pubitemid 46293798)
78. Ward H. One-to-one counselling for STI prevention: not so much whether as how. Sex Transm Infect 2007; 83(1): 1. (Pubitemid 46293797)
79. U.S. Preventative Services Task Force Behavioral counseling to prevent sexually transmitted infections: US Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149 (7): 491-6.
80. Koblin B, Chesney M, Coates T. Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study. Lancet 2004; 364 (9428): 41-50. doi:10.1016/S0140-6736(04)16588-4 (Pubitemid 38968624)